This effect may be relevant for therapeutic application of the mGluR2 inhibition against demyelinating disorders in PNS, such as Charcot Marie Tooth disease type 1 (CMT1). The gene discussed is GRM2; the disease is Charcot-Marie-Tooth disease type 1.